Rockville, United States
OpGen, Inc., a precision medicine company based in Rockville, Maryland, is a notable player in the Biotechnology and Health Care sectors. Founded in 2002, the company is at the forefront of developing molecular diagnostics aimed at combating infectious diseases and optimizing the treatment of drug-resistant infections.
Focusing on highly multiplexed syndromic molecular panels, OpGen aims to address the global challenge of antimicrobial resistance (AMR) and improve antibiotic stewardship. The innovative diagnostic solutions offered by the company have the potential to dramatically enhance patient care and curb the spread of multidrug-resistant microorganisms (MDROs).
Recently, OpGen secured a $3.00M Post-IPO Equity investment on 25 March 2024. This investment was led by David E Lazar, providing the company with fresh capital to further its mission. This investment highlights continued investor confidence in OpGen's cutting-edge molecular microbiology technology and its potential impact on global health.
